Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years
NEW YORK and MAINZ, GERMANY, March 14, 2023 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to provide a single booster dose of the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Children | Clinical Trials | COVID-19 | Emergency Medicine | Food and Drug Administration (FDA) | Germany Health | Pfizer | Pharmaceuticals